10-Q: OpGen Shifts to FinTech, Reports Q1 Loss Amid Restructuring
Quarterly Report
OpGen, Inc. reported a net loss of $0.4 million in Q1 2025, a significant shift from profit, as it fully transitioned from precision medicine to financial services and technology, with no revenue generated from legacy operations.
Summary
- OpGen, Inc. has fully repositioned its business from precision medicine to the financial services and technology industry, operating through its wholly-owned subsidiary, CapForce International Holdings Ltd.
- The company reported no revenue for the three months ended March 31, 2025, compared to $168,149 in the same period of 2024, reflecting the wind-down of legacy operations.
- Net loss for Q1 2025 was $408,133, a decrease from a net income of $287,967 in Q1 2024 (which included a $2.1 million gain on impairment adjustment).
- Operating expenses significantly decreased by 73% to $522,846 in Q1 2025 from $1,913,464 in Q1 2024, primarily due to scaling down legacy operations.
- Cash and cash equivalents stood at $1.1 million as of March 31, 2025, down from $1.3 million at December 31, 2024.
- Net cash used in operating activities improved significantly, decreasing to $197,872 in Q1 2025 from $1,084,050 in Q1 2024.
- The company was delisted from Nasdaq and its common stock now trades on the OTC Markets Group Expert Market; it plans to reapply for Nasdaq relisting.
- CapForce received a $5.0 million investment in a client's equity as consideration for listing sponsorship services, with a contractual agreement for additional shares if the IPO valuation is lower.
- OpGen's subsidiary, CapForce, entered a Joint Venture Agreement with European Credit Investment Bank (ECIB) on April 3, 2025, to form CapForce EC Capital Markets Ltd. for a stock trading and digital investment banking platform.
Sentiment
Score: 4
Explanation: The company is undergoing a complete and dramatic strategic pivot, which involves significant risks and a current lack of revenue. While cost reductions are positive, the absence of revenue, delisting from Nasdaq, and reliance on a single investor for future funding indicate high uncertainty. The new joint venture and equity investment are positive steps, but their impact on future profitability is yet to be proven. The overall sentiment is cautious due to the early stage of the new business and the challenges faced during the transition.
Positives
- Significant reduction in operating expenses by 73% ($1.4 million decrease) in Q1 2025 compared to Q1 2024, indicating successful cost optimization during the business transition.
- Net cash used in operating activities decreased substantially by 81.8% ($886,178 decrease) in Q1 2025 compared to Q1 2024, reflecting improved operational cash burn.
- Secured an investment of $5.0 million in equity securities of a client for listing sponsorship services, with a contractual guarantee for additional shares if the IPO valuation is less than $5.0 million.
- Entered into a Joint Venture Agreement with European Credit Investment Bank (ECIB) to develop and operate a stock trading and digital investment banking platform, signaling progress in the new strategic direction.
- Access to an additional $7.0 million in common stock sales to AEI Capital Ltd. until December 31, 2025, providing a funding source for future operations.
- Successfully settled outstanding indebtedness with the EIB and Curetis in August 2024, resulting in a gain on extinguishment of debt exceeding $9.7 million.
Negatives
- Reported zero revenue in Q1 2025, a 100% decrease from $168,149 in Q1 2024, indicating a complete cessation of revenue from legacy operations without immediate replacement from the new business.
- Shifted from a net income of $287,967 in Q1 2024 to a net loss of $408,133 in Q1 2025, primarily due to the absence of the prior year's large impairment gain and lack of revenue.
- Delisted from Nasdaq and now trades on the OTC Markets Group Expert Market, which is eligible only for unsolicited quotes and lacks market makers, potentially impacting liquidity and investor confidence.
- The investor in the October 2023 Purchase Agreement for Series D Preferred Stock remains in breach, with $750,000 of the $1.0 million purchase price unpaid.
- Cash and cash equivalents decreased to $1.1 million at March 31, 2025, from $1.3 million at December 31, 2024.
- Accumulated deficit increased to $293.9 million at March 31, 2025, from $293.5 million at December 31, 2024.
Risks
- Uncertainty regarding the company's liquidity and working capital requirements, including cash needs over the next 12 months.
- Challenges in executing and achieving the benefits of the strategic direction under new leadership and Board of Directors.
- Difficulty in identifying and realizing the benefits of potential strategic transactions.
- Adverse effects on business condition and results of operations from general economic and market conditions, including investor concerns regarding inflation.
- The absence of market makers for common stock, which is currently quoted on the OTC Expert Market and eligible only for unsolicited quotes, may hinder liquidity.
- Potential significant effect on stock price from third-party actions if common stock is traded on a market other than the OTC Expert Market.
- Compliance with U.S. regulations applicable to the new financial services and technology business.
- Uncertainty regarding future revenue and expenses in the new business segment.
- No assurance that the company will be able to relist with The Nasdaq Stock Market LLC.
- The inventory of legacy products (Unyvero system instruments and components) is fully reserved due to uncertainty surrounding net realizable value and future demand.
- Use of federal net operating loss (NOL) carryforwards (approximately $227.1 million at December 31, 2024) may be subject to annual limitation under Section 382 of the Internal Revenue Code.
- The $5.0 million investment in equity securities of a privately held entity is subject to significant judgment and market risk, as its estimated fair value is not based on observable inputs and relies on an anticipated IPO valuation.
Future Outlook
The company anticipates funding its operations primarily through financing arrangements with AEI Capital Ltd., including the August 2024 Securities Purchase Agreement, which provides access to up to $7.0 million in additional common stock sales until December 31, 2025. Management believes this will allow the company to fund operations for more than 12 months. The company plans to apply for relisting with The Nasdaq Stock Market LLC after meeting relevant listing requirements and expects to generate revenues from CapForce's listing sponsorship and consulting services, as well as other business ventures in cross-border securities trading, advanced computational model-enabled investment banking advisory, asset management services, and FinTech-enabled capital table management solutions.
Management Comments
- We believe that the expectations reflected in the forward-looking statements are reasonable, but we cannot guarantee future results, level of activity, performance or achievements.
- We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
- We anticipate funding our operations primarily through financing arrangements with AEI Capital Ltd.
- We believe that our current cash and our access to additional cash under the August 2024 Securities Purchase Agreement will allow the Company to fund operations in excess of 12 months from the issuance date of these financial statements.
- The Company plans to apply for relisting with The Nasdaq Stock Market LLC after meeting the relevant Nasdaq listing requirements.
Industry Context
OpGen's complete pivot from precision medicine to financial services and technology, specifically digital investment banking and listing sponsorship, represents a dramatic shift. This move positions the company in a highly competitive and rapidly evolving FinTech landscape, aiming to capitalize on demand for digital solutions in capital markets. The formation of CapForce and the joint venture with ECIB indicate an aggressive entry into this new sector, targeting international companies and cross-border trading. This contrasts sharply with its former focus on infectious disease diagnostics, placing it in a completely different competitive set and regulatory environment.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Executive Officer, Chairman, Director | David E. Lazar | John Tan Honjian | August 2024 | Mr. Lazar sold his Series E Preferred Stock and rights to AEI Capital Ltd. and subsequently resigned from these roles, though he maintains a role as President. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board of Directors Appointment | A new Board of Directors was appointed in March 2024 in connection with the March 2024 Purchase Agreement, with David E. Lazar initially appointed Chairman. | March 2024 | Signifies a complete change in strategic direction and oversight, aligning with the company's repositioning. |
Legal Proceedings
- To the best of our knowledge, we are not currently a party to any legal proceedings that, individually or in the aggregate, are deemed to be material to our financial condition or results of operations.
Related Party Transactions
- AEI Capital Ltd. is the company's controlling stockholder and has entered into multiple financing agreements, including the August 2024 Securities Purchase Agreement and its amendment, providing the company with access to capital.
- CapForce, a wholly-owned subsidiary, entered into an Agreement of Assignment of Mandate with AEI Capital Ltd. for direct listing sponsorship advisory services, resulting in a $5.0 million investment in a client's equity.
- The CEO of AEI Capital Ltd. and OpGen, Inc. serves as a member of the Board of Directors of the client in which CapForce holds a $5.0 million equity investment, making the client a related party.
Stakeholder Impact
- **Shareholders**: Experience significant dilution from past and potential future common stock sales to AEI Capital Ltd. Face increased risk due to the complete business pivot and delisting from Nasdaq. Potential for future value creation if the new FinTech strategy is successful, but also high risk of further losses.
- **Employees**: The company has scaled down legacy operations and operates virtually, indicating a significant reduction in headcount and a shift in operational structure.
- **Customers (Legacy)**: The precision medicine business has been wound down, with assets sold, meaning former customers for diagnostic products and laboratory services are no longer served by OpGen.
- **Customers (New)**: International companies seeking listing sponsorship and consultancy services, as well as participants in the planned stock trading and digital investment banking platforms, are the new target customers.
- **Creditors**: The settlement of the EIB and Curetis debt has resolved a significant liability, improving the company's balance sheet in that regard. Short-term insurance financing is being managed.
Next Steps
- Continue to scale down legacy operations while repositioning to operate in the financial services and technology industry.
- Develop and operate a stock trading platform and digital investment banking platform through the CapForce EC Capital Markets Ltd. joint venture.
- Apply for relisting with The Nasdaq Stock Market LLC after meeting relevant listing requirements.
- Utilize the right to sell up to $7.0 million of additional common stock to AEI Capital Ltd. to fund operations.
- Evaluate the effects of ASU No. 2025-05: Financial Instruments-Credit Losses for adoption in fiscal year ending December 31, 2026.
- Monitor the investment in the client's equity for observable price changes or impairment, particularly in anticipation of an initial public offering.
Key Dates
| Date | Description |
|---|---|
| 2016-12-31 | Curetis entered into a loan financing facility from the European Investment Bank (EIB). |
| 2023-10-31 | Company entered into a Preferred Stock Purchase Agreement (October 2023 Purchase Agreement) with a single investor for Series D Preferred Stock. |
| 2023-10-01 | Investor funded $250,000 of the October 2023 Purchase Agreement in November 2023. |
| 2023-12-31 | EIB issued a notice stating Curetis was in default and demanded repayment from OpGen as guarantor. |
| 2024-01-02 | AEI Capital Ltd. entered into a Letter of Engagement with a privately held company (the Client) to provide listing advisory services. |
| 2024-03-01 | Company entered into the March 2024 Purchase Agreement with David E. Lazar for Series E Convertible Preferred Stock. |
| 2024-03-31 | End of comparative quarterly period for financial statements. |
| 2024-04-01 | Company entered into an employment agreement with Mr. Lazar to act as CEO. |
| 2024-04-30 | Mr. Lazar paid $350,000 for an additional 350,000 shares of Series E Preferred Stock. |
| 2024-05-20 | Company effected a 1-for-10 reverse stock split of its common stock. |
| 2024-06-05 | Company received a letter from Nasdaq regarding non-compliance with minimum stockholders equity requirement. |
| 2024-07-31 | Mr. Lazar sold 550,000 shares of Series E Preferred Stock and rights to AEI Capital Ltd. |
| 2024-08-01 | AEI Capital Ltd. paid $2.45 million for the remaining 2,450,000 shares of Series E Preferred Stock. |
| 2024-08-16 | Company received a letter from Nasdaq Hearings Panel denying continued listing request. |
| 2024-08-31 | All 3,000,000 shares of Series E Preferred Stock were converted into 7,200,000 shares of common stock. Mr. Lazar resigned as CEO, Chairman, and Director, but maintains role as President. Company paid and settled outstanding indebtedness with EIB and Curetis. Company entered into August 2024 Securities Purchase Agreement with AEI Capital Ltd. |
| 2024-09-30 | No shares of Series E Preferred Stock remained outstanding. Company sold 1,079,109 shares of common stock to AEI Capital Ltd. for gross proceeds of $2.0 million. |
| 2024-10-02 | CapForce entered into an Agreement of Assignment of Mandate with AEI Capital in respect of Direct Listing Sponsorship Advisory Services. |
| 2024-10-31 | Company and AEI Capital Ltd. entered into a First Amendment to the August 2024 Securities Purchase Agreement, extending the ability to sell shares until December 31, 2025, and granting rights to sell two additional tranches of $3.0 million each. |
| 2024-12-19 | Nasdaq Listing and Hearing Review Council affirmed the Panel's decision to delist the company's securities. |
| 2024-12-31 | Previous balance sheet date for financial statements. Extended period for AEI Capital Ltd. to purchase common stock. |
| 2025-03-31 | End of current quarterly period for financial statements. |
| 2025-04-03 | CapForce entered into a Joint Venture Agreement with the European Credit Investment Bank (ECIB). |
| 2025-05-31 | Company entered into a similar short-term insurance financing agreement with a principal amount of approximately $284,304. |
| 2025-10-01 | Date of filing of the 10-Q report. 10,071,286 shares of common stock outstanding. |
| 2026-12-31 | Effective date for ASU No. 2025-05: Financial Instruments-Credit Losses. |
Recommendation
holdOpGen is in the midst of a high-risk, high-reward strategic pivot from a failed precision medicine business to the nascent FinTech sector. While the company has significantly reduced operating expenses and secured some initial funding and a joint venture, it currently generates no revenue and has been delisted from Nasdaq. The reliance on a single controlling shareholder (AEI Capital Ltd.) for future funding, the unfulfilled Series D preferred stock agreement, and the early stage of its new ventures introduce substantial uncertainty. A 'hold' recommendation is appropriate for investors who are already exposed and willing to tolerate extreme risk, as the potential for significant upside exists if the FinTech strategy succeeds, but the downside risks, including further dilution and operational challenges, are equally substantial. New investors should exercise extreme caution due to the speculative nature of the current business model and the company's financial history.
Keywords
FinTech, Financial Services, Digital Investment Banking, Capital Table Management, Listing Sponsorship, SEC Filing, 10-Q, Quarterly Report, OpGen, OPGN, Strategic Repositioning, Nasdaq Delisting, OTC Markets, Joint Venture, CapForce, AEI Capital Ltd., European Credit Investment Bank, Net Loss, Operating Expenses, Liquidity, Equity Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.